Actively Recruiting
Contribution of Oncogenetics in Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2
Led by Centre Hospitalier Universitaire de la Réunion · Updated on 2024-08-22
300
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Breast cancer is the most common cancer among women in mainland France and Reunion, responsible for significant mortality despite generally having a good prognosis. This research focuses on the genetic aspects of breast cancer in Reunion, particularly the prevalence of a specific BRCA2 gene mutation found in the local population. Understanding this mutation could help adapt genetic consultations and preventive measures for breast cancer in the region. Participants in this study will provide a blood sample to detect the Reunion-specific BRCA2 mutation (c.2612C>A mutation of exon 11). The study is interventional and aims to determine how common this mutation is among breast cancer patients in Reunion. Only patients diagnosed with a first or second breast cancer during the inclusion period and living in Reunion are eligible. Participants will be assessed at the time of inclusion through genetic testing of the blood sample. The main outcome measured is the prevalence of the Reunion BRCA2 mutation in individuals diagnosed with breast cancer. The study does not involve masking or placebo groups. Participation involves consenting to genetic testing and sharing relevant health information, with no long-term treatment or follow-up detailed.
CONDITIONS
Brief Title
Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Domiciled in Reunion at the time of diagnosis
- Diagnosed with a first breast cancer (in situ or invasive) confirmed by pathological examination during the inclusion period or diagnosed with a second breast cancer (in situ or invasive) contralateral or at least 5 years after remission of the first
- Agreed to participate in the study
- Affiliates or beneficiaries of a social security scheme
You will not qualify if you...
- Carriers of breast lymphoma
- Minor patients or patients under guardianship or curatorship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of inclusion
Participants provide a blood sample for BRCA2 mutation detection to determine the prevalence of the Réunion mutation in the BRCA2 gene.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Mireille IRABE
Saint-Pierre, France, 97432
Actively Recruiting
Research Team
M
Mireille IRABE
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here